メインコンテンツに移動
City clarity

Transparency vs clarity: the Mifid swaps conundrum

Participants want better OTC transparency, but say Esma’s efforts at clarity could muddy the picture

Sometimes you just can’t do right for doing wrong – and regulators are no exception. As the European Securities and Markets Authority discovered when it tried to clarify Europe’s labyrinthine rules on transparency for over-the-counter derivatives transactions back in 2017. In launching an opinion document that attempted to disambiguate the rules for OTC trade transparency in the second Markets in

コンテンツを印刷またはコピーできるのは、有料の購読契約を結んでいるユーザー、または法人購読契約の一員であるユーザーのみです。

これらのオプションやその他の購読特典を利用するには、info@risk.net にお問い合わせいただくか、こちらの購読オプションをご覧ください: http://subscriptions.risk.net/subscribe

現在、このコンテンツをコピーすることはできません。詳しくはinfo@risk.netまでお問い合わせください。

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

無料メンバーシップの内容をお知りになりたいですか?ここをクリック

パスワードを表示
パスワードを非表示にする

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

ログイン
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here